Tags

Type your tag names separated by a space and hit enter

A meta-analysis of placebo-controlled trials of omega-3 fatty acid augmentation in schizophrenia: Possible stage-specific effects.
Ann Clin Psychiatry. 2015 Nov; 27(4):289-96.AC

Abstract

BACKGROUND

Omega-3 fatty acids have shown promise as an adjunctive treatment for schizophrenia. However, efficacy across studies has been inconsistent. We conducted a meta-analysis of published controlled studies with the goal of detecting different efficacy profiles at various stages of schizophrenia.

METHODS

An online search was conducted for randomized, double-blind, placebo-controlled clinical trials, and a meta-analysis was conducted.

RESULTS

Ten studies met the criteria for inclusion. Among patients in the prodromal phase of schizophrenia, omega-3 supplementation reduced psychotic symptom severity and lowered conversion rates to first-episode psychosis. In patients with first-episode schizophrenia, omega-3 decreased nonpsychotic symptoms, required lower antipsychotic medication dosages, and improved early treatment response rates. Omega-3 had mixed results in patients with stable chronic schizophrenia, with only some patients experiencing significant benefits. Among patients with chronic schizophrenia, use of omega-3 fatty acids both by those experiencing acute exacerbations and those who had discontinued antipsychotic medications resulted in worsening of psychotic symptoms.

CONCLUSIONS

The data suggest that omega-3 fatty acids may be efficacious in reducing clinical symptoms for patients in the earlier stages of schizophrenia (prodrome and first episode), while producing mixed results for patients in the chronic stages. Based on these results, omega-3 fatty acids would not be recommended for acute exacerbations in patients with chronic schizophrenia nor for relapse prevention after discontinuation of antipsychotics.

Authors+Show Affiliations

Department of Neurology and Psychiatry, Saint Louis University School of Medicine, St. Louis, MO USA. E-MAIL: chena@slu.edu.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis

Language

eng

PubMed ID

26554370

Citation

Chen, Alexander T., et al. "A Meta-analysis of Placebo-controlled Trials of Omega-3 Fatty Acid Augmentation in Schizophrenia: Possible Stage-specific Effects." Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists, vol. 27, no. 4, 2015, pp. 289-96.
Chen AT, Chibnall JT, Nasrallah HA. A meta-analysis of placebo-controlled trials of omega-3 fatty acid augmentation in schizophrenia: Possible stage-specific effects. Ann Clin Psychiatry. 2015;27(4):289-96.
Chen, A. T., Chibnall, J. T., & Nasrallah, H. A. (2015). A meta-analysis of placebo-controlled trials of omega-3 fatty acid augmentation in schizophrenia: Possible stage-specific effects. Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists, 27(4), 289-96.
Chen AT, Chibnall JT, Nasrallah HA. A Meta-analysis of Placebo-controlled Trials of Omega-3 Fatty Acid Augmentation in Schizophrenia: Possible Stage-specific Effects. Ann Clin Psychiatry. 2015;27(4):289-96. PubMed PMID: 26554370.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A meta-analysis of placebo-controlled trials of omega-3 fatty acid augmentation in schizophrenia: Possible stage-specific effects. AU - Chen,Alexander T, AU - Chibnall,John T, AU - Nasrallah,Henry A, PY - 2015/11/12/entrez PY - 2015/11/12/pubmed PY - 2016/9/7/medline SP - 289 EP - 96 JF - Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists JO - Ann Clin Psychiatry VL - 27 IS - 4 N2 - BACKGROUND: Omega-3 fatty acids have shown promise as an adjunctive treatment for schizophrenia. However, efficacy across studies has been inconsistent. We conducted a meta-analysis of published controlled studies with the goal of detecting different efficacy profiles at various stages of schizophrenia. METHODS: An online search was conducted for randomized, double-blind, placebo-controlled clinical trials, and a meta-analysis was conducted. RESULTS: Ten studies met the criteria for inclusion. Among patients in the prodromal phase of schizophrenia, omega-3 supplementation reduced psychotic symptom severity and lowered conversion rates to first-episode psychosis. In patients with first-episode schizophrenia, omega-3 decreased nonpsychotic symptoms, required lower antipsychotic medication dosages, and improved early treatment response rates. Omega-3 had mixed results in patients with stable chronic schizophrenia, with only some patients experiencing significant benefits. Among patients with chronic schizophrenia, use of omega-3 fatty acids both by those experiencing acute exacerbations and those who had discontinued antipsychotic medications resulted in worsening of psychotic symptoms. CONCLUSIONS: The data suggest that omega-3 fatty acids may be efficacious in reducing clinical symptoms for patients in the earlier stages of schizophrenia (prodrome and first episode), while producing mixed results for patients in the chronic stages. Based on these results, omega-3 fatty acids would not be recommended for acute exacerbations in patients with chronic schizophrenia nor for relapse prevention after discontinuation of antipsychotics. SN - 1547-3325 UR - https://www.unboundmedicine.com/medline/citation/26554370/A_meta_analysis_of_placebo_controlled_trials_of_omega_3_fatty_acid_augmentation_in_schizophrenia:_Possible_stage_specific_effects_ L2 - https://www.aacp.com/article/abstract/a-meta-analysis-of-placebo-controlled-trials-of-omega-3-fatty-acid-augmentation-in-schizophrenia-possible-stage-specific-effects/ DB - PRIME DP - Unbound Medicine ER -